Evidence map›Paper›PMID 40074312›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2024

Complement C5/C5a in the diagnosis and treatment of Graves

Min Zhu, Bingxuan Wu, Changci Chen-Zhao, Haiyan Chen, Wei Xiong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Min ZhuDepartment of Ophthalmology, Third Xiangya Hospital, Central South University, Changsha 410013, China. 228312186@csu.edu.cn.
Bingxuan WuDepartment of Ophthalmology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Changci Chen-ZhaoDepartment of Ophthalmology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Haiyan ChenDepartment of Ophthalmology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Wei XiongDepartment of Ophthalmology, Third Xiangya Hospital, Central South University, Changsha 410013, China. weixiong420@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesGraves' ophthalmopathy is a complex organ-specific autoimmune disease with an unclear pathogenesis. Complement component 5/5a (C5/C5a), a key element of the component system, may play a significant role in the disease's pathological process. This study aims to investigate the causal relationship between C5/C5a and Graves' ophthalmopathy using Mendelian randomization (MR) to provide new theoretical insights for its diagnosis and treatment.

methodsUtilizing summary data from genome-wide association study (GWAS), C5/C5a was designated as the exposure factor and Graves' ophthalmopathy as the outcome. The causal relationship between C5/C5a and Graves' ophthalmopathy was analyzed, and colocalization analysis was performed to determine the posterior probability of hypothesis (PPH) and verify the genetic association between C5 and Graves' ophthalmopathy.

resultsThe Wald ratio model showed a significant positive correlation between C5 and Graves' ophthalmopathy (

conclusionsElevated levels of C5/C5a significantly increase the risk of developing Graves' ophthalmopathy. Targeting complement C5 with inhibitors may effectively reduce the risk of Graves' ophthalmopathy.

Indexed as

Complement C5Complement C5aGraves OphthalmopathyGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMendelian Randomization AnalysisPolymorphism, Single NucleotideComplement C5Complement C5acolocalization analysiscomplement C5complement C5aGraves’ ophthalmopathyMendelian randomization

Identifiers

PMID40074312
PMCPMC11897966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.